Subjects harboring presenilin familial Alzheimer’s disease mutations exhibit diverse white matter biochemistry alterations

American Journal of Neurodegenerative Diseases

Volumn 2, Issue 3, 2013, Pages 187-207

  Roher, Alex E ^a   Maarouf, Chera L ^a   Malek Ahmadi, Michael ^a   Wilson, Jeffrey ^b   Kokjohn, Tyler A ^a,c   Daugs, Ian D ^a   Whiteside, Charisse M ^a   Kalback, Walter M ^a   Macias, MiMi P ^a   Jacobson, Sandra A ^a,d   Sabbagh, Marwan N ^a,d   Ghetti, Bernardino ^e   Beach, Thomas G ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid precursor protein; Amyloid beta; Familial Alzheimer s disease; Gray matter; Presenilin; Sporadic Alzheimer s disease; White matter; secretase

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN E; GAMMA SECRETASE; NEUROTROPHIC FACTOR; NICASTRIN; PRESENILIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN HEMORRHAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE EXPRESSION; GENE MUTATION; GRAY MATTER; HUMAN; HUMAN TISSUE; LONG TERM POTENTIATION; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL DENSITY; PROTEIN STRUCTURE; PSEN1 GENE; PSEN2 GENE; WESTERN BLOTTING;

EID: 84980052302     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Wortmann M. Dementia: a global health priority - highlights from an ADI and World Health Organization report. Alzheimers Res Ther 2012; 4: 40.
2. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Willson R, Rosser M, Owen M and Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-706.
3. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HA, Haines JL, Perkicak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM and St George-Hyslop PH. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754-760.
4. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, Crowley AC, Fu YH, Galas D, Nemens E, Wijsman EM, Bird TD, Schellenberg GD and Tanzi RE. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269: 973-977.
5. Zhang H, Ma Q, Zhang YW and Xu H. Proteolytic processing of Alzheimer's beta-amyloid precursor protein. J Neurochem 2012; 120 Suppl 1: 9-21.
6. De Strooper B, Iwatsubo T and Wolfe MS. Presenilins and gamma-Secretase: Structure, Function, and Role in Alzheimer Disease. Cold Spring Harb Perspect Med 2012; 2: a006304.
7. Haapasalo A and Kovacs DM. The many substrates of presenilin/gamma-secretase. J Alzheimers Dis 2011; 25: 3-28.
8. Larner AJ and Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol 2006; 253: 139-158.
9. Larner AJ and Doran M. Genotype-phenotype relationships of presenilin-1 mutations in Alzheimer's disease: an update. J Alzheimers Dis 2009; 17: 259-265.
10. Ryan NS and Rossor MN. Correlating familial Alzheimer's disease gene mutations with clinical phenotype. Biomark Med 2010; 4: 99-112.
11. Mann DM, Pickering-Brown SM, Takeuchi A, and Iwatsubo T. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol 2001; 158: 2165-2175.
12. Elder GA, Gama Sosa MA, De Gasperi R, Dickstein DL and Hof PR. Presenilin transgenic mice as models of Alzheimer's disease. Brain Struct Funct 2010; 214: 127-143.
13. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ and Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 1997; 89: 629-639.
14. Gama Sosa MA, Gasperi RD, Rocher AB, Wang AC, Janssen WG, Flores T, Perez GM, Schmeidler J, Dickstein DL, Hof PR and Elder GA. Age-related vascular pathology in transgenic mice expressing presenilin 1-associated familial Alzheimer's disease mutations. Am J Pathol 2010; 176: 353-368.
15. Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJ, Trumbauer ME, Chen HY, Price DL, Van der Ploeg LH and Sisodia SS. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature 1997; 387: 288-292.
16. Strobel G. Expanding the Network, DIAN Starts Showing Longitudinal Data. (10-11-12). http://www.alzforum.org/new/detail.asp?id=3290.
17. Brunetti A, Postiglione A, Tedeschi E, Ciarmiello A, Quarantelli M, Covelli EM, Milan G, Larobina M, Soricelli A, Sodano A and Alfano B. Measurement of global brain atrophy in Alzheimer's disease with unsupervised segmentation of spin-echo MRI studies. J Magn Reson Imaging 2000; 11: 260-266.
18. Smith CD, Snowdon DA, Wang H and Markesbery WR. White matter volumes and periventricular white matter hyperintensities in aging and dementia. Neurology 2000; 54: 838-842.
19. DeCarli C, Grady CL, Clark CM, Katz DA, Brady DR, Murphy DG, Haxby JV, Salerno JA, Gillette JA, Gonzalez-Aviles A and Rapoport SI. Comparison of positron emission tomography, cognition, and brain volume in Alzheimer's disease with and without severe abnormalities of white matter. J Neurol Neurosurg Psychiatry 1996; 60: 158-167.
20. Kawamura J, Meyer JS, Terayama Y and Weathers S. Leuko-araiosis and cerebral hypoperfusion compared in elderly normals and Alzheimer's dementia. J Am Geriatr Soc 1992; 40: 375-380.
21. Bartzokis G. Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging 2011; 32: 1341-1371.
22. Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR Jr, Weiner M and DeCarli C. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol 2010; 67: 1370-1378.
23. Provenzano FA, Muraskin J, Tosto G, Narkhede A, Wasserman BT, Griffith EY, Guzman VA, Meier IB, Zimmerman ME and Brickman AM. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol 2013; 70: 455-461.
24. Gurol ME, Viswanathan A, Gidicsin C, Hedden T, Martinez-Ramirez S, Dumas A, Vashkevich A, Ayres AM, Auriel E, van Etten E, Becker A, Carmasin J, Schwab K, Rosand J, Johnson KA and Greenberg SM. Cerebral amyloid angiopathy burden associated with leukoaraiosis: A positron emission tomography/magnetic resonance imaging study. Ann Neurol 2012; Epub ahead of print.
25. Gold BT, Johnson NF, Powell DK and Smith CD. White matter integrity and vulnerability to Alzheimer's disease: Preliminary findings and future directions. Biochim Biophys Acta 2012; 1822: 416-422.
26. Back SA, Kroenke CD, Sherman LS, Lawrence G, Gong X, Taber EN, Sonnen JA, Larson EB and Montine TJ. White matter lesions defined by diffusion tensor imaging in older adults. Ann Neurol 2011; 70: 465-476.
27. Beach TG, Walker R and McGeer EG. Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia 1989; 2: 420-436.
28. Hachinski VC, Potter P and Merskey H. Leuko-araiosis. Arch Neurol 1987; 44: 21-23.
29. Di Paola M, Spalletta G and Caltagirone C. In vivo structural neuroanatomy of corpus callosum in Alzheimer's disease and mild cognitive impairment using different MRI techniques: a review. J Alzheimers Dis 2010; 20: 67-95.
30. Matsusue E, Sugihara S, Fujii S, Ohama E, Kinoshita T and Ogawa T. White matter changes in elderly people: MR-pathologic correlations. Magn Reson Med Sci 2006; 5: 99-104.
31. Kalback W, Esh C, Castano EM, Rahman A, Kokjohn T, Luehrs DC, Sue L, Cisneros R, Gerber F, Richardson C, Bohrmann B, Walker DG, Beach TG and Roher AE. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res 2004; 26: 525-539.
32. Reisberg B, Pattschull-Furlan A, Franssen E, Sclan SG, Kluger A, Dingcong L and Ferris SH. Dementia of the Alzheimer type recapitulates ontogeny inversely on specific ordinal and temporal parameters. Neurodevelopment, Aging and Cognition 1992; 1: 345-369.
33. Braak H and Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol 1996; 92: 197-201.
34. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 2004; 25: 5-18.
35. Braak H and Del Tredici K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging 2004; 25: 19-23.
36. Choi SJ, Lim KO, Monteiro I and Reisberg B. Diffusion tensor imaging of frontal white matter microstructure in early Alzheimer's disease: a preliminary study. J Geriatr Psychiatry Neurol 2005; 18: 12-19.
37. Stricker NH, Schweinsburg BC, Delano-Wood L, Wierenga CE, Bangen KJ, Haaland KY, Frank LR, Salmon DP and Bondi MW. Decreased white matter integrity in late-myelinating fiber pathways in Alzheimer's disease supports retrogenesis. Neuroimage 2009; 45: 10-16.
38. O'Dwyer L, Lamberton F, Bokde AL, Ewers M, Faluyi YO, Tanner C, Mazoyer B, O'Neill D, Bartley M, Collins DR, Coughlan T, Prvulovic D and Hampel H. Multiple indices of diffusion identifies white matter damage in mild cognitive impairment and Alzheimer's disease. PLoS One 2011; 6: e21745.
39. Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, Anthony J, Watson D, Luehrs DC, Sue L, Walker D, Emmerling M, Goux W and Beach T. Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 2002; 41: 11080-11090.
40. Roher AE, Kuo YM, Esh C, Knebel C, Weiss N, Kalback W, Luehrs DC, Childress JL, Beach TG, Weller RO and Kokjohn TA. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med 2003; 9: 112-122.
41. Castano EM, Maarouf CL, Wu T, Leal MC, Whiteside CM, Lue LF, Kokjohn TA, Sabbagh MN, Beach TG and Roher AE. Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations. Neurochem Int 2013; 62: 145-156.
42. Maarouf CL, Daugs ID, Spina S, Vidal R, Kokjohn TA, Patton RL, Kalback WM, Luehrs DC, Walker DG, Castano EM, Beach TG, Ghetti B and Roher AE. Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations. Mol Neurodegener 2008; 3: 20.
43. Fox NC, Kennedy AM, Harvey RJ, Lantos PL, Roques PK, Collinge J, Hardy J, Hutton M, Stevens JM, Warrington EK and Rossor MN. Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Brain 1997; 120: 491-501.
44. Abe K. Clinical and molecular analysis of neurodegenerative diseases. Tohoku J Exp Med 1997; 181: 389-409.
45. Takao M, Ghetti B, Murrell JR, Unverzagt FW, Giaccone G, Tagliavini F, Bugiani O, Piccardo P, Hulette CM, Crain BJ, Farlow MR and Heyman A. Ectopic white matter neurons, a developmental abnormality that may be caused by the PSEN1 S169L mutation in a case of familial AD with myoclonus and seizures. J Neuropathol Exp Neurol 2001; 60: 1137-1152.
46. O'Riordan S, McMonagle P, Janssen JC, Fox NC, Farrell M, Collinge J, Rossor MN and Hutchinson M. Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology 2002; 59: 1108-1110.
47. Marcon G, Giaccone G, Cupidi C, Balestrieri M, Beltrami CA, Finato N, Bergonzi P, Sorbi S, Bugiani O and Tagliavini F. Neuropathological and clinical phenotype of an Italian Alzheimer family with M239V mutation of presenilin 2 gene. J Neuropathol Exp Neurol 2004; 63: 199-209.
48. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L, Connor DJ, Sabbagh MN and Rogers J. The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank 2008; 9: 229-245.
49. Maarouf CL, Daugs ID, Kokjohn TA, Walker DG, Hunter JM, Kruchowsky JC, Woltjer R, Kaye J, Castano EM, Sabbagh MN, Beach TG and Roher AE. Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS One 2011; 6: e27291
50. Berengut D. Some Small-Sample Properties of the Student t Confidence Intervals. The American Statistician 1981; 35: 144-147.
51. Fairweather WR. A Method of Obtaining an Exact Confidence Interval for the Common Mean of Several Normal Populations. Journal of the Royal Statistical Society Series C (Applied Statistics) 1972; 21: 229-233.
52. Ringman JM, O'Neill J, Geschwind D, Medina L, Apostolova LG, Rodriguez Y, Schaffer B, Varpetian A, Tseng B, Ortiz F, Fitten J, Cummings JL and Bartzokis G. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain 2007; 130: 1767-1776.
53. Bendlin BB, Ries ML, Canu E, Sodhi A, Lazar M, Alexander AL, Carlsson CM, Sager MA, Asthana S and Johnson SC. White matter is altered with parental family history of Alzheimer's disease. Alzheimers Dement 2010; 6: 394-403.
54. Smith CD, Chebrolu H, Andersen AH, Powell DA, Lovell MA, Xiong S and Gold BT. White matter diffusion alterations in normal women at risk of Alzheimer's disease. Neurobiol Aging 2010; 31: 1122-1131.
55. Li M, Chen L, Lee DH, Yu LC and Zhang Y. The role of intracellular amyloid beta in Alzheimer's disease. Prog Neurobiol 2007; 83: 131-139.
56. Decker H, Lo KY, Unger SM, Ferreira ST and Silverman MA. Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons. J Neurosci 2010; 30: 9166-9171.
57. Liao MC, Ahmed M, Smith SO and Van Nostrand WE. Degradation of amyloid beta protein by purified myelin basic protein. J Biol Chem 2009; 284: 28917-28925.
58. Kotarba AE, Aucoin D, Hoos MD, Smith SO and Van Nostrand WE. Fine mapping of the amyloid beta-protein binding site on myelin basic protein. Biochemistry 2013; 52: 2565-2573.
59. Van Vickle GD, Esh CL, Kokjohn TA, Patton RL, Kalback WM, Luehrs DC, Beach TG, Newel AJ, Lopera F, Ghetti B, Vidal R, Castano EM and Roher AE. Presenilin-1 280Glu-->Ala mutation alters C-terminal APP processing yielding longer abeta peptides: implications for Alzheimer's disease. Mol Med 2008; 14: 184-194.
60. Quiroz YT, Stern CE, Reiman EM, Brickhouse M, Ruiz A, Sperling RA, Lopera F and Dickerson BC. Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers. J Neurol Neurosurg Psychiatry 2013; 84: 556-561.
61. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling RA, Dickerson B, Stern CE, Tirado V, Munoz C, Reiman RA, Huentelman MJ, Alexander GE, Langbaum JB, Kosik KS, Tariot PN and Lopera F. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012; 11: 1048-1056.
62. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S and Morris JC. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804.
63. Amtul Z, Lewis PA, Piper S, Crook R, Baker M, Findlay K, Singleton A, Hogg M, Younkin L, Younkin SG, Hardy J, Hutton M, Boeve BF, Tang-Wai D and Golde TE. A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch. Neurobiol Dis 2002; 9: 269-273.
64. Shioi J, Georgakopoulos A, Mehta P, Kouchi Z, Litterst CM, Baki L and Robakis NK. FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta. J Neurochem 2007; 101: 674-681.
65. Page RM, Baumann K, Tomioka M, Perez-Revuelta BI, Fukumori A, Jacobsen H, Flohr A, Luebbers T, Ozmen L, Steiner H and Haass C. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J Biol Chem 2008; 283: 677-683.
66. Dermaut B, Kumar-Singh S, Engelborghs S, Theuns J, Rademakers R, Saerens J, Pickut BA, Peeters K, van den Broeck M, Vennekens K, Claes S, Cruts M, Cras P, Martin JJ, Van Broeckhoven C and De Deyn PP. A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann Neurol 2004; 55: 617-626.
67. Kopan R, Schroeter EH, Weintraub H and Nye JS. Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proc Natl Acad Sci U S A 1996; 93: 1683-1688.
68. Woo HN, Park JS, Gwon AR, Arumugam TV and Jo DG. Alzheimer's disease and Notch signaling. Biochem Biophys Res Commun 2009; 390: 1093-1097.
69. Zhang C, Wu B, Beglopoulos V, Wines-Samuelson M, Zhang D, Dragatsis I, Sudhof TC and Shen J. Presenilins are essential for regulating neurotransmitter release. Nature 2009; 460: 632-636.
70. Suzuki K, Hayashi Y, Nakahara S, Kumazaki H, Prox J, Horiuchi K, Zeng M, Tanimura S, Nishiyama Y, Osawa S, Sehara-Fujisawa A, Saftig P, Yokoshima S, Fukuyama T, Matsuki N, Koyama R, Tomita T and Iwatsubo T. Activity-dependent proteolytic cleavage of neuroligin-1. Neuron 2012; 76: 410-422.
71. Saura CA, Servian-Morilla E and Scholl FG. Presenilin/gamma-secretase regulates neurexin processing at synapses. PLoS One 2011; 6: e19430.
72. Bot N, Schweizer C, Ben Halima S and Fraering PC. Processing of the synaptic cell adhesion molecule neurexin-3beta by Alzheimer disease alpha- and gamma-secretases. J Biol Chem 2011; 286: 2762-2773.
73. Bottos A, Destro E, Rissone A, Graziano S, Cordara G, Assenzio B, Cera MR, Mascia L, Bussolino F and Arese M. The synaptic proteins neurexins and neuroligins are widely expressed in the vascular system and contribute to its functions. Proc Natl Acad Sci U S A 2009; 106: 20782-20787.
74. De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 2007; 8: 141-146.
75. Wolfe MS. When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 2007; 8: 136-140.
76. Goux WJ, Rodriguez S and Sparkman DR. Analysis of the core components of Alzheimer paired helical filaments. A gas chromatography/mass spectrometry characterization of fatty acids, carbohydrates and long-chain bases. FEBS Lett 1995; 366: 81-85.
77. Goux WJ, Rodriguez S and Sparkman DR. Characterization of the glycolipid associated with Alzheimer paired helical filaments. J Neurochem 1996; 67: 723-733.
78. Goux WJ, Liu B, Shumburo AM, Parikh S and Sparkman DR. A quantitative assessment of glycolipid and protein associated with paired helical filament preparations from Alzheimer's diseased brain. J Alzheimers Dis 2001; 3: 455-466.
79. Gray EG, Paula-Barbosa M and Roher A. Alzheimer's disease: paired helical filaments and cytomembranes. Neuropathol Appl Neurobiol 1987; 13: 91-110.
80. Hull M, Fiebich BL, Dykierek P, Schmidtke K, Nitzsche E, Orszagh M, Deuschl G, Moser E, Schumacher M, Lucking C, Berger M and Bauer J. Early-onset Alzheimer's disease due to mutations of the presenilin-1 gene on chromosome 14: a 7-year follow-up of a patient with a mutation at codon 139. Eur Arch Psychiatry Clin Neurosci 1998; 248: 123-129.
81. Nikisch G, Hertel A, Kiessling B, Wagner T, Krasz D, Hofmann E and Wiedemann G. Three-year follow-up of a patient with early-onset Alzheimer's disease with presenilin-2 N141I mutation - case report and review of the literature. Eur J Med Res 2008; 13: 579-584.
82. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F and Tariot PN. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011; 26 Suppl 3: 321-329.
83. Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, Oliver A, Quaid K, Ringman JM, Rossor MN, Salloway S, Schofield PR, Selsor NJ, Sperling RA, Weiner MW, Xiong C, Moulder KL and Buckles VD. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) 2012; 2: 975-984.
84. Mullard A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nat Rev Drug Discov 2012; 11: 657-660.
85. Sperling R and Aisen P. Anti-amyloid treatment in Asymptomatic* AD A4 Trial. (09-28-2012). http://alzheimer.wustl.edu/education/berg/berg2012/Slides/Sperling.pdf.
86. D'Onofrio G, Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Paroni G, Cascavilla L, Seripa D and Pilotto A. Advances in the identification of gamma-secretase inhibitors for the treatment of Alzheimer's disease. Expert Opin Drug Discov 2012; 7: 19-37.
87. Wolfe MS. gamma-Secretase as a target for Alzheimer's disease. Adv Pharmacol 2012; 64: 127-153.
88. Tomita T. [Development of Alzheimer's disease treatment based on the molecular mechanism of gamma-secretase activity]. Rinsho Shinkeigaku 2012; 52: 1165-1167.
89. Lleo A and Saura CA. gamma-secretase substrates and their implications for drug development in Alzheimer's disease. Curr Top Med Chem 2011; 11: 1513-1527.
90. Hopkins CR. ACS chemical neuroscience molecule spotlight on ELND006: another gamma-secretase inhibitor fails in the clinic. ACS Chem Neurosci 2011; 2: 279-280.